Junshi Biosciences' Four Drugs Placed on China's Insurance Drug List

MT Newswires Live12-08

Four drugs under Shanghai Junshi Biosciences (HKG:1877, SHA:688180) were included in China's National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance list, according to a Sunday disclosure on the Hong Kong bourse.

The pharmaceutical company's Shanghai and Hong Kong shares both rose less than 1% during Monday's afternoon trade.

The drugs included on the list are toripalimab injection or Tuoyi, adalimumab injection or Junmaikang, deuremidevir hydrobromide tablets or Mindewei, and ongericimab injection or Junshida.

Tuoyi is the only anti-PD-1 monoclonal antibody on the list for the treatment of renal cancer, triple-negative breast cancer and melanoma.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment